NovoSeven RT is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX >5 Bethesda Units (BU);
in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration;
in patients with acquired haemophilia;
in patients with congenital FVII deficiency;
in patients with Glanzmann's thrombasthenia with antibodies to GP IIb-IIIa and/or HLA, and with past or present refractoriness to platelets transfusions.